cobalt(II)
Dotaz
Zobrazit nápovědu
Východiska: Waldenströmova makroglobulinemie (WM) je velmi vzácné onemocnění s incidencí desetkrát nižší, než má mnohočetný myelom. Incidence WM je také podstatně nižší než u hlavních jednotek ze skupiny CD20+ low-grade lymfomů, do níž WM morfologicky patří. Vzácnost WM je důvodem, proč registrační studie nových léků používaných pro mnohočetný myelom nebo častější CD20+ low-grade lymfomy nezahrnují WM. Informace o účinnosti inhibitorů proteazomu u WM lze čerpat z popisů případů, malých sérií pacientů a nečetných klinických studií fáze II. Cílem této práce je informovat o našich zkušenostech s léčbou WM bortezomibem a posléze ixazomibem a předložit přehled zahraničních publikací o přínosu léků ze skupiny inhibitorů proteazomu pro léčbu WM. Případ: Popisujeme pacienta, který po 8 letech asymptomatického průběhu WM měl v 74 letech první fulminantní progresi se závažnou pancytopenií. Pro léčbu 1. linie jsme použili dexametazon a rituximab a po zmírnění pancytopenie posléze bendamustin. Dosáhli jsme poklesu monoklonálního imunoglobulinu typu IgM (M-IgM) ze 40 g/l až na hodnotu 6,9 g/l, tedy parciální remise (PR) s normálními hodnotami krevního obrazu. Po 29 měsících PR byl přijat opět s fulminantním relapsem WM provázeným závažnou pancytopenií. Rituximab a dexametazon byly páteří léčby, k nim jsme přidali bortezomib pro jeho podstatně menší myelosupresi ve srovnání s alkylačními cytostatiky. Léčba trojkombinací bortezomib, rituximab a dexametazon byla účinná, ale po pěti cyklech bylo nutné ukončit podávání bortezomibu pro závažné projevy neurotoxicity. Od sedmého cyklu byla zahájena léčba ixazomibem. Pacient absolvoval dalších sedm cyklů (měsíců) léčby ve složení ixazomib, rituximab a dexametazon, celkem tedy 14 cyklů léčby. Výsledky: M-IgM poklesl z 30 g/l při zahájení léčby na 4,0 g/l při ukončení léčby a dále klesl až na hodnotu 2,8 g/l v 8. měsíci po ukončení léčby. Bylo dosaženo hlubšího poklesu koncentrace M-IgM než po léčbě 1. linie a pacient nyní splňuje kritéria velmi dobré parciální remise. Závěr: Dle popsané zkušenosti a uvedeného přehledu publikací hodnotících inhibitory proteazomu u WM vyniká kombinace ixazomibu s rituximabem a dexametazonu velmi dobrou tolerancí a vysokou účinností, blížící se účinnosti kombinace rituximabu s bendamustinem. Své místo má tato kombinace zejména u pacientů s WM a cytopenií.
Background: Waldenström’s macroglobulinemia (WM) is a very rare disease with an incidence 10times lower than that of multiple myeloma. The incidence of WM is also significantly lower than that of the other CD20+ low-grade lymphomas. The rarity of WM is the reason why registration studies of new drugs used for multiple myeloma or the more common CD20+low-grade lymphomas do not cover WM. Data on the efficacy of proteasome inhibitors in WM can be drawn from case descriptions, small series of patients and a few phase II clinical trials. The aim of this case report and review is to inform about our experience with the treatment of WM with bortezomib and then ixazomib and to present an overview of publications on proteasome inhibitors in WM. Case: We describe a patient who, after 8 years of asymptomatic course of WM, had the first fulminant progression with severe pancytopenia at the age of 74 years. For the first-line treatment, he was treated with dexamethasone and rituximab, and after alleviation of pancytopenia, with bendamustine. Monoclonal immunoglobulin IgM (M-IgM) dropped from 40 g/L to the level as low as 6.9 g/L, which meant partial remission (PR) accompanied with normal blood count values. After 29 months of PR, the patient experienced a fulminant relapse of WM, accompanied by severe pancytopenia. Rituximab and dexamethasone were the backbone of treatment with addition of bortezomib for its significantly lower myelosuppression compared to alkylating agents. Treatment with the triple combination of bortezomib, rituximab, and dexamethasone was effective, however, after five cycles, bortezomib had to be discontinued for severe neurotoxicity. The sixth cycle contained rituximab and dexamethasone, and from the seventh cycle, ixazomib was started. The patient underwent seven cycles (months) of treatment consisting of ixazomib, rituximab and dexamethasone (14 cycles of treatment in total). Results: M-IgM decreased from 30 g/L at the beginning of the treatment to 4.0 g/L at the end of treatment and further decreased to a value of 2.8 g/L at the eighth month after the end of the treatment. A deeper decrease in M-IgM than after first-line treatment was achieved and the patient now meets the criteria for a very good partial remission. Conclusion: According to the described experience and according to the review of publications evaluating proteasome inhibitors in WM, the combination of ixazomib with rituximab and dexamethasone excels with very good tolerance and high efficacy, approaching the efficacy of the combination of rituximab with bendamustine. This combination has its place particularly in patients with WM and cytopenia.
- Klíčová slova
- ixazomib,
- MeSH
- bortezomib farmakologie terapeutické užití MeSH
- diagnostické zobrazování metody MeSH
- glycin farmakologie terapeutické užití MeSH
- inhibitory proteasomu farmakologie terapeutické užití MeSH
- lidé MeSH
- pancytopenie etiologie terapie MeSH
- pozitronová emisní tomografie metody MeSH
- progrese nemoci MeSH
- recidiva MeSH
- senioři MeSH
- sloučeniny boru farmakologie terapeutické užití MeSH
- Waldenströmova makroglobulinemie * diagnóza farmakoterapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- kazuistiky MeSH
The most frequent alterations in plasma amino acid concentrations in type 1 and type 2 diabetes are decreased L-serine and increased branched-chain amino acid (BCAA; valine, leucine, and isoleucine) levels. The likely cause of L-serine deficiency is decreased synthesis of 3-phosphoglycerate, the main endogenous precursor of L-serine, due to impaired glycolysis. The BCAA levels increase due to decreased supply of pyruvate and oxaloacetate from glycolysis, enhanced supply of NADH + H+ from beta-oxidation, and subsequent decrease in the flux through the citric acid cycle in muscles. These alterations decrease the supply of α-ketoglutarate for BCAA transamination and the activity of branched-chain keto acid dehydrogenase, the rate-limiting enzyme in BCAA catabolism. L-serine deficiency contributes to decreased synthesis of phospholipids and increased synthesis of deoxysphinganines, which play a role in diabetic neuropathy, impaired homocysteine disposal, and glycine deficiency. Enhanced BCAA levels contribute to increased levels of aromatic amino acids (phenylalanine, tyrosine, and tryptophan), insulin resistance, and accumulation of various metabolites, whose influence on diabetes progression is not clear. It is concluded that amino acid concentrations should be monitored in patients with diabetes, and systematic investigation is needed to examine the effects of L-serine and glycine supplementation on diabetes progression when these amino acids are decreased.
OBJECTIVE: Glycine encephalopathy, also known as nonketotic hyperglycinemia (NKH), is an inherited neurometabolic disorder with variable clinical course and severity, ranging from infantile epileptic encephalopathy to psychiatric disorders. A precise phenotypic characterization and an evaluation of predictive approaches are needed. METHODS: Longitudinal clinical and biochemical data of 25 individuals with NKH from the patient registry of the International Working Group on Neurotransmitter Related Disorders were studied with in silico analyses, pathogenicity scores, and molecular modeling of GLDC and AMT variants. RESULTS: Symptom onset (p < 0.01) and diagnosis occur earlier in life in severe NKH (p < 0.01). Presenting symptoms affect the age at diagnosis. Psychiatric problems occur predominantly in attenuated NKH. Onset age ≥ 3 months (66% specificity, 100% sensitivity, area under the curve [AUC] = 0.87) and cerebrospinal fluid (CSF)/plasma glycine ratio ≤ 0.09 (57% specificity, 100% sensitivity, AUC = 0.88) are sensitive indicators for attenuated NKH, whereas CSF glycine concentration ≥ 116.5μmol/l (100% specificity, 93% sensitivity, AUC = 0.97) and CSF/plasma glycine ratio ≥ 0.15 (100% specificity, 64% sensitivity, AUC = 0.88) are specific for severe forms. A ratio threshold of 0.128 discriminates the overlapping range. We present 10 new GLDC variants. Two mild variants resulted in attenuated, whereas 2 severe variants or 1 mild and 1 severe variant led to severe phenotype. Based on clinical, biochemical, and genetic parameters, we propose a severity prediction model. INTERPRETATION: This study widens the phenotypic spectrum of attenuated NKH and expands the number of pathogenic variants. The multiparametric approach provides a promising tool to predict disease severity, helping to improve clinical management strategies. ANN NEUROL 2022;92:292-303.
Although glyphosate is widely used for weed pest control, it might have negative side effects on natural enemies. Wolf spiders are one of the most representative predators found on soybean crops in Uruguay, preying on a wide variety of potential pests. However, the sublethal effects that pesticides might have on this group have been poorly explored for South American species. Herein, we explored the sublethal effects of glyphosate on the functional response of the wolf spider Hogna cf. bivittata against three potential pest insects, namely ant (Acromyrmex sp.), caterpillar (Anticarsia gemmatalis), and cricket (Miogryllus sp.). We contaminated residually adult females of the species Hogna cf. bivittata with glyphosate (Roundup®) and compared their functional response against non-contaminated spiders. We did not observe any mortality during the study. We found that overall Hogna cf. bivittata showed a functional response type II against crickets and caterpillars but no functional response to ants. Contaminated spiders killed less ants and caterpillars in comparison to the control group, probably as a consequence of the irritating effects of glyphosate. We did not observe differences in functional response to crickets at the evaluated densities, probably as a consequence of the low capture rate against this prey. Although glyphosate does not specifically target spiders, it might have negative sublethal effects on native predators such as Hogna cf. bivittata. Further studies should explore effect of glyphosate on other native predators from South American crops.
- MeSH
- Formicidae MeSH
- glycin analogy a deriváty toxicita MeSH
- Gryllidae MeSH
- můry MeSH
- pavouci účinky léků MeSH
- pesticidy toxicita MeSH
- predátorské chování účinky léků MeSH
- zemědělské plodiny MeSH
- zvířata MeSH
- Check Tag
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Uruguay MeSH
PURPOSE: The double-blind, placebo-controlled, phase III TOURMALINE-MM1 study demonstrated a statistically significant improvement in progression-free survival with ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd in patients with relapsed or refractory multiple myeloma. We report the final analyses for overall survival (OS). PATIENTS AND METHODS: Patients were randomly assigned to ixazomib-Rd (n = 360) or placebo-Rd (n = 362), stratified by number of prior therapies (1 v 2 or 3), previous proteasome inhibitor (PI) exposure (yes v no), and International Staging System disease stage (I or II v III). OS (intent-to-treat population) was a key secondary end point. RESULTS: With a median follow-up of 85 months, median OS with ixazomib-Rd versus placebo-Rd was 53.6 versus 51.6 months (hazard ratio, 0.939; P = .495). Lower hazard ratios, indicating larger magnitude of OS benefit with ixazomib-Rd versus placebo-Rd, were seen in predefined subgroups: refractory to any (0.794) or last (0.742) treatment line; age > 65-75 years (0.757); International Staging System stage III (0.779); 2/3 prior therapies (0.845); high-risk cytogenetics (0.870); and high-risk cytogenetics and/or 1q21 amplification (0.862). Following ixazomib-Rd versus placebo-Rd, 71.7% versus 69.9% of patients received ≥ 1 anticancer therapy, of whom 24.7% versus 33.9% received daratumumab and 71.8% versus 76.9% received PIs (next-line therapy: 47.5% v 55.8%). Rates of new primary malignancies were similar with ixazomib-Rd (10.3%) and placebo-Rd (11.9%). There were no new or additional safety concerns. CONCLUSION: Median OS values in both arms were the longest reported in phase III studies of Rd-based triplets in relapsed or refractory multiple myeloma at the time of this analysis; progression-free survival benefit with ixazomib-Rd versus placebo-Rd did not translate into a statistically significant OS benefit on intent-to-treat analysis. OS benefit was greater in subgroups with adverse prognostic factors. OS interpretation was confounded by imbalances in subsequent therapies received, especially PIs and daratumumab.
- MeSH
- analýza přežití MeSH
- dexamethason aplikace a dávkování škodlivé účinky MeSH
- dvojitá slepá metoda MeSH
- glycin aplikace a dávkování škodlivé účinky analogy a deriváty MeSH
- kvalita života MeSH
- lenalidomid aplikace a dávkování škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom farmakoterapie mortalita patologie MeSH
- následné studie MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- senioři MeSH
- sloučeniny boru aplikace a dávkování škodlivé účinky MeSH
- staging nádorů MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
Cadmium (Cd) is a heavy metal that occurs in all areas of the environment, including the food chain. In the body, it causes oxidative stress by producing free radicals that are harmful to the cells. Grape seed extract (GSE) contains a wide range of biologically active components that help to neutralize the adverse effects of free radicals. In this study, the effects of GSE prepared form semi-resistant grapevine cultivar Cerason, which is rich in phenolics, on biochemical markers of brown rats exposed to the effects of cadmium were monitored. GSE increased the plasma antioxidant activity and, in the kidneys and the liver, Cd content was significantly lowered by GSE co-administration. Accordingly, the increase in creatinine content and alanine aminotransferase activity and the decrease of catalase and superoxide dismutase activities caused by cadmium were slowed down by GSE co-administration. The results of this work reveal that grape seed extract offers a protective effect against the intake of heavy metals into the organism.
- MeSH
- alanintransaminasa krev MeSH
- antioxidancia analýza MeSH
- aspartátaminotransferasy krev MeSH
- biologické markery metabolismus MeSH
- extrakt ze semen vinné révy farmakologie MeSH
- fytonutrienty analýza MeSH
- játra účinky léků enzymologie metabolismus MeSH
- kadmium krev MeSH
- katalasa metabolismus MeSH
- kreatinin krev MeSH
- ledviny účinky léků metabolismus MeSH
- metalothionein metabolismus MeSH
- močovina krev MeSH
- potkani Wistar MeSH
- semena rostlinná chemie MeSH
- superoxiddismutasa metabolismus MeSH
- zdraví * MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. METHODS: A total of 344 patients treated with IRD (N = 127) or RD (N = 217) were selected for analysis from the Czech Registry of Monoclonal Gammopathies (RMG). Descriptive statistics were used to assess patient's characteristics associated with the respective therapy. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS). Survival endpoints were plotted using Kaplan-Meier methodology at 95% Greenwood confidence interval. Univariable and multivariable Cox proportional hazards models were used to evaluate the effect of treatment regimens and the significance of uneven variables. Statistical tests were performed at significance level 0.05. RESULTS: In the whole cohort, median PFS for IRD was 17.5 and for RD was 11.5 months favoring the all-oral triplet, p = 0.005; in patients within relapse 1-3, the median PFS was 23.1 vs 11.6 months, p = 0.001. The hazard ratio for PFS was 0.67 (95% confidence interval [CI] 0.51-0.89, p = 0.006). The PFS advantage translated into improved OS for patients treated with IRD, median 36.6 months vs 26.0 months (p = 0.008). The overall response rate (ORR) was 73.0% in the IRD group vs 66.2% in the RD group with a complete response rate (CR) of 11.1% vs 8.8%, and very good partial response (VGPR) 22.2% vs 13.9%, IRD vs RD respectively. The IRD regimen was most beneficial in patients ≤75 years with ISS I, II, and in the first and second relapse. Patients with the presence of extramedullary disease did not benefit from IRD treatment (median PFS 6.5 months). Both regimens were well tolerated, and the incidence of total as well as grade 3/4 toxicities was comparable. CONCLUSIONS: Our analysis confirms the results of the TOURMALINE-MM1 study and shows benefit of all-oral triplet IRD treatment versus RD doublet. It demonstrates that the addition of ixazomib to RD improves key survival endpoints in patients with RRMM in a routine clinical setting.
- MeSH
- aplikace orální MeSH
- chemorezistence MeSH
- dexamethason farmakologie terapeutické užití MeSH
- doba přežití bez progrese choroby MeSH
- dospělí MeSH
- glycin analogy a deriváty farmakologie terapeutické užití MeSH
- Kaplanův-Meierův odhad MeSH
- lenalidomid farmakologie terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie mortalita patologie MeSH
- mnohočetný myelom farmakoterapie mortalita patologie MeSH
- následné studie MeSH
- prospektivní studie MeSH
- protokoly protinádorové kombinované chemoterapie farmakologie terapeutické užití MeSH
- registrace statistika a číselné údaje MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sloučeniny boru farmakologie terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Geografické názvy
- Česká republika MeSH
Two novel Co(II) fenamato complexes containing bathocuproine (bcp), namely [Co(bcp)(flu)2] (1) and [Co(bcp)(nif)2] (2) (flu = flufenamato, nif = niflumato) were synthesized and characterized by elemental analysis, single-crystal X-ray structure analysis as well as absorption and fluorescence spectroscopy. Investigation of their molecular structure revealed that both complexes are isostructural and form analogous complex molecules, with a Co(II) atom hexacoordinated by two nitrogen atoms of bcp and four oxygen atoms of two chelate bonded flu (1) and nif (2) ligands in a distorted octahedral arrangement. Surprisingly, the results of cytotoxicity experiments on four cancer cell lines (HeLa, HT-29, PC-3 and MCF-7) have revealed that despite similar structure of the complexes, the nif complex exhibits significantly higher activity, being the most effective against the PC-3 cell line (IC50 (MTT) = 6.11 ± 1.95 μM). Further studies performed on PC-3 cell line have shown that the mechanism of the cytotoxic action of nif complex (2) might involve activation of autophagic processes and apoptosis, while for its flu analogue (1) apoptosis was detected.
- MeSH
- apoptóza účinky léků MeSH
- autofagie účinky léků MeSH
- fenantroliny chemická syntéza farmakologie MeSH
- kobalt chemie MeSH
- komplexní sloučeniny chemická syntéza farmakologie MeSH
- kontrolní body fáze G1 buněčného cyklu účinky léků MeSH
- kyselina flufenamová analogy a deriváty farmakologie MeSH
- lidé MeSH
- ligandy MeSH
- molekulární struktura MeSH
- nádorové buněčné linie MeSH
- protinádorové látky chemická syntéza farmakologie MeSH
- screeningové testy protinádorových léčiv MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Amyotrofická laterální skleróza (ALS) je progresivní neurodegenerativní onemocnění (ND) motoneuronů v mozkové kůře, mozkovém kmeni a míše vedoucí ke ztrátě svalové kontroly a úmrtí vlivem respiračního selhání většinou do 3–5 let od stanovení diagnózy. Většina případů ALS je sporadická (sALS), avšak 5–10 % tvoří případy familiární (fALS). Asi 20 % případů fALS a 2–7 % případů sALS je spojeno s mutací SOD1 genu, který kóduje enzym měď-zinek superoxiddismutázu 1 (SOD1). Nejběžnější volný radikál vznikající v lidském těle je málo reaktivní a tedy nikoliv příliš škodlivý superoxid mající však schopnost spontánní přeměny dismutací na peroxid vodíku. SOD1 tuto dismutaci urychluje a vzniklý peroxid vodíku je odstraňován navazujícími reakcemi. Mutace postihující SOD1 vedou k poruše homeostázy mědi v míše zvířecích (myších) modelů ALS. V současnosti je v Austrálii testována sloučenina Cu2+ diacetyl-di, N4-methylthiosemicarbazon v I/II fázi klinické studie u ALS pacientů. Předpokládá se, že tato molekula by mohla fungovat nejen u případů ALS s mutací SOD1 (SOD1-ALS) jako nosič mědi nebo zinku umožňující jejich interakci se SOD1, a tím správnou funkci enzymu, ale i jako sloučenina vychytávající peroxynitrit. Léčebný potenciál tedy není limitován pouze na SOD1-ALS či ALS obecně, ale jako sloučenina snižující poškození buněk oxidativním a nitrosativním stresem by mohla najít využití i při terapii dalších ND.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of motor neurons in the cerebral cortex, brain stem, and spinal cord leading to loss of muscle control and death from respiratory failure occurring mostly within 3-5 years of the disease diagnosis. The majority of ALS cases are sporadic (sALS); however, 5-10% are familial cases (fALS). Approximately 20% of fALS cases and 2-7% of sALS cases are associated with a mutation in the SOD1 gene that encodes the copper-zinc superoxide dismutase 1 enzyme (SOD1). The most common free radical arising in the human body is a not very reactive, and thus, not a very harmful superoxide which, however, is capable of spontaneous conversion by dismutation to hydrogen peroxide. SOD1 accelerates this dismutation and the produced hydrogen peroxide is eliminated by successive reactions. The mutations affecting SOD1 lead to copper dyshomeostasis in the spinal cord of animal (mice) models of ALS. Currently, the Cu2+ diacetyl-di, N4-methylthiosemicarbazone molecule is being tested in Australia in a phase I/II clinical trial in patients with ALS. It is assumed that this molecule could work not only in cases of ALS with SOD1 mutation (SOD1-ALS) as a copper or zinc carrier allowing their interaction with SOD1, and thus, it's the proper function of the enzyme, but also as a compound for peroxynitrite uptake. As a result, its therapeutic use appears not to be limited only to cases of SOD1-ALS or ALS in general, but it might also have an effect as a compound to reduce cell damage by oxidative and nitrosative stress in other neurodegenerative diseases.
- MeSH
- amyotrofická laterální skleróza * patologie terapie MeSH
- homeostáza MeSH
- lidé MeSH
- měď * metabolismus MeSH
- mutace genetika MeSH
- organokovové sloučeniny MeSH
- riluzol terapeutické užití MeSH
- superoxiddismutasa MeSH
- thiosemikarbazony MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH
The role of hydrogen sulfide (H2S) is addressed in Xenopuslaevis oocytes. Three enzymes involved in H2S metabolism, cystathionine β-synthase, cystathionine γ-lyase, and 3-mercaptopyruvate sulfurtransferase, were detected in prophase I and metaphase II-arrested oocytes and drove an acceleration of oocyte meiosis resumption when inhibited. Moreover, meiosis resumption is associated with a significant decrease in endogenous H2S. On another hand, a dose-dependent inhibition was obtained using the H2S donor, NaHS (1 and 5 mM). NaHS impaired translation. NaHS did not induce the dissociation of the components of the M-phase promoting factor (MPF), cyclin B and Cdk1, nor directly impacted the MPF activity. However, the M-phase entry induced by microinjection of metaphase II MPF-containing cytoplasm was diminished, suggesting upstream components of the MPF auto-amplification loop were sensitive to H2S. Superoxide dismutase and catalase hindered the effects of NaHS, and this sensitivity was partially dependent on the production of reactive oxygen species (ROS). In contrast to other species, no apoptosis was promoted. These results suggest a contribution of H2S signaling in the timing of amphibian oocytes meiosis resumption.
- MeSH
- apoptóza účinky léků MeSH
- cyklin B metabolismus MeSH
- cystathionin-beta-synthasa antagonisté a inhibitory metabolismus MeSH
- cystathionin-gama-lyasa antagonisté a inhibitory metabolismus MeSH
- cytoplazma metabolismus MeSH
- faktor podporující zrání metabolismus MeSH
- fosfatasy cdc25 metabolismus MeSH
- katalasa metabolismus MeSH
- meióza účinky léků MeSH
- metafáze účinky léků MeSH
- oocyty chemie enzymologie metabolismus MeSH
- profáze meiózy I účinky léků MeSH
- proteinkinasy metabolismus MeSH
- proteiny buněčného cyklu metabolismus MeSH
- proteiny Xenopus metabolismus MeSH
- reaktivní formy kyslíku metabolismus MeSH
- signální transdukce účinky léků MeSH
- sulfan metabolismus MeSH
- sulfidy metabolismus farmakologie MeSH
- sulfurtransferasy antagonisté a inhibitory metabolismus MeSH
- superoxiddismutasa metabolismus MeSH
- viabilita buněk účinky léků MeSH
- Xenopus laevis MeSH
- zvířata MeSH
- Check Tag
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
